Patient P-01661

Synthetic patientNBL-101 · Day 117 · 25–34 · F · baseline S03Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Improving

Inflammatory state

Stable

Nutritional resilience

Improving

Discontinuation risk

55%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S03
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −15% vs expected — Dietary Support Protocol NP-02
Day 44 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 45 SC-12 recommended — Supportive Compound SC-12
Day 46 Patient accepted — Started SC-12 in the companion
Day 48 Tolerance state changed — Unstable → Improving
Day 52 No meaningful change — Supportive Compound SC-12
Day 60 GI-04 recommended — GI Support Protocol GI-04
Day 61 Patient accepted — Started GI-04 in the companion
Day 69 GI symptom burden −20% vs expected — GI Support Protocol GI-04
Day 75 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 44.

Primary contributors, last 14 days

Nutritional resilience+11
Toxicity-5
GI instability-4

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −15%
Supportive Compound SC-12Day 45
Result: no meaningful change
GI Support Protocol GI-04Day 60
Result: symptom burden −20%

LIFE OS recommendation

Monitoring Escalation ME-01

75%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 50 and rising
Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 51
- WearableHRV 20 ms, trending down
Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 43
Autonomic recovery ↓45
- WearableResting HR 84 bpm
- Wearable2,510 steps/day
Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.5 · butyrate capacity 47/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 18 ms
Sleep: 7.4 h
Steps: 1,968
Resting HR: 82 bpm

Daily log: GI score 50, nutritional resilience 45, adherence 47.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01336	60%	S03	GI-04	improved	51
P-01330	56%	S14	GI-04	improved	47
P-01879	56%	S14	SC-12	improved	51
P-01573	54%	S14	GI-04	improved	49
P-01406	53%	S18	GI-04	improved	50
P-01614	52%	S14	GI-04	improved	53
P-01429	51%	S09	GI-04	improved	45
P-01496	51%	S14	SC-12	improved	46
P-01624	51%	S14	GI-04	improved	52
P-01692	51%	S14	NP-02	improved	49
P-01709	51%	S14	GI-04	improved	43
P-01327	49%	S01	GI-04	improved	56